Acute Lymphoblastic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Acute Lymphoblastic Leukemia stocks.

Recent Signals

Date Stock Signal Type
2021-04-14 ABUS 20 DMA Resistance Bearish
2021-04-14 ABUS MACD Bullish Signal Line Cross Bullish
2021-04-14 AIKI Stochastic Buy Signal Bullish
2021-04-14 AIKI Bullish Engulfing Bullish
2021-04-14 CLLS Shooting Star Candlestick Bearish
2021-04-14 CLLS 20 DMA Resistance Bearish
2021-04-14 CLLS Bollinger Band Squeeze Range Contraction
2021-04-14 CLLS 180 Bearish Setup Bearish Swing Setup
2021-04-14 ERYP Bollinger Band Squeeze Range Contraction
2021-04-14 IMGN Slingshot Bearish Bearish Swing Setup
2021-04-14 IMGN Lower Bollinger Band Walk Weakness
2021-04-14 JAZZ Crossed Above 20 DMA Bullish
2021-04-14 JAZZ Crossed Above 50 DMA Bullish
2021-04-14 TCRR Crossed Above 20 DMA Bullish
2021-04-14 TCRR Crossed Above 200 DMA Bullish
Related Industries: Biotechnology

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated.In most cases, the cause is unknown. Genetic risk factors may include Down syndrome, Li-Fraumeni syndrome, or neurofibromatosis type 1. Environmental risk factors may include significant radiation exposure or prior chemotherapy. Evidence regarding electromagnetic fields or pesticides is unclear. Some hypothesize that an abnormal immune response to a common infection may be a trigger. The underlying mechanism involves multiple genetic mutations that results in rapid cell division. The excessive immature lymphocytes in the bone marrow interfere with the production of new red blood cells, white blood cells, and platelets. Diagnosis is typically based on blood tests and bone marrow examination.ALL is typically treated initially with chemotherapy aimed at bringing about remission. This is then followed by further chemotherapy typically over a number of years. Additional treatments may include intrathecal chemotherapy or radiation therapy if spread to the brain has occurred. Stem cell transplantation may be used if the disease recurs following standard treatment. Additional treatments such as immunotherapy are being studied.ALL affected about 876,000 people globally in 2015 and resulted in about 111,000 deaths. It occurs most commonly in children, particularly those between the ages of two and five. In the United States it is the most common cause of cancer and death from cancer among children. ALL is notable for being the first disseminated cancer to be cured. Survival for children increased from under 10% in the 1960s to 90% in 2015. Survival rates remain lower for babies (50%) and adults (35%).

More about Acute Lymphoblastic Leukemia
Browse All Tags